Abstract
In the present study, a novel [(AMP)(VO)(H2O)2] complex was formed through chemical reactions between oxidovanadium(IV)sulfate and adenosine monophosphate. This complex was characterized using various analyses, including microanalytical, molar conductivity, spectroscopic (solid reflectance and FTIR), magnetic susceptibility, thermogravimetric (TGA), X-ray powder diffraction (XRD), and scanning (SEM) and transmission (TEM) electron microscopy. The in vivo antidiabetic activity of the oxidovanadium(IV) complex was determined using streptozotocin-induced rats. The results suggested that the synthesized complex can be used as an antidiabetic agent based on the observed biochemical effects.
Highlights
A number of potential pharmaceutical agents contain metal-binding sites, which can bind or interact with metal ions and may affect their vital activities [1]
Complex (Group IV) had a 4.34%decrease compared with Group II, whereas the treatment of diabetic rats by oxidovanadium(IV) sulfate itself was increased by 5.78%
Complex (Group IV), a significant increase of 18.01% was observed relative to Group II, whereas the treatment with oxidovanadium(IV) sulfate itself caused an increase of 14.37%
Summary
A number of potential pharmaceutical agents contain metal-binding sites, which can bind or interact with metal ions and may affect their vital activities [1]. 2 ofthe progression of diabetes type I, while type II results from a lack of insulin sensitivity in target tissues [7,8,9,10]. Therapeutic goal for this disease to stimulate or mimic the production of insulin, complexesthe with various coordination modesisand their structure–function relationship havewhich been would or,inatvitro least,approaches lessen its many studiedameliorate using boththe in disease vivo and [5,6]. From a lack of insulin sensitivity in target tissues studied by Headrick al. The et therapeutic for this disease to stimulate mimic the production of current synthesis, antidiabetic of a novel insulin, study whichexplores would the ameliorate thestructure disease elucidation, or, at least,and lessen its manyeffects symptoms and oxidovanadium(IV)–AMP complex. Comorbidities [11,12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
